Markets & Finance

First Albany Ups Supergen to Buy

First Albany upgraded Supergen (SUPG) to buy.

Analyst Lucy Lu says she's upgrading from neutral as MGI Pharmaceuticals licensed the worldwide rights to Supergen's anti-cancer therapeutic Dacogen. She notes MGI will make a $40 million equity investment in Supergen and pay up to $45 million in regulatory milestones and royalties of 20% to 30% based on Dacogen sales.

Lu says MGI is the ideal partner for Dacogen; she cites its sales force and the successful commercialization of Aloxi, an oncology supportive care product. With MGI on board, Lu sees Dacogen becoming a more significant part of Supergen's valuation. She cut the $1.62 2004 loss estimate to a $1.57 loss, and trimmed the $1.03 2005 loss to a 78-cent loss.

The Aging of Abercrombie & Fitch
blog comments powered by Disqus